The first week of March 2026 marked a melancholy chapter in uniQure N.V.'s (QURE) story as its stock plunged more than 40% to a low of $8.73 on a disappointing regulatory update on AMT-130, an investigational gene therapy for Huntington's disease.
Huntington's disease (HD) is a rare, fatal, neurodegenerative genetic disorder that affects motor function and leads to behavioral symptoms and cognitive decline in young adults. Over time, it results in total physical and mental deterioration. Roughly 75,000 people in the U.S., Europe and the UK are affected by HD, making this one of the largest clinical unmet needs in the rare disease field.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.